Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multi-centric, Open-label, Comparator-controlled Study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Next Previous
X
Search
Trial Profile

Randomized, Multi-centric, Open-label, Comparator-controlled Study to evaluate the efficacy and safety of RABIMABs administered in conjunction with Vaxirab N for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docaravimab/miromavimab (Primary) ; Docaravimab/miromavimab (Primary) ; Rabies immune globulin
  • Indications Rabies
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Cadila Healthcare

    • Most Recent Events

    • 17 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2020 Primary endpoint (a. Proportion of subjects with RFFIT titre more than or equal to 0.5 IU/ml on Days 14 who receiving RABIMABs + Vaxirab N and Immunoglobulins (Imogam) + Vaxirab N) has been met according to the results published in the Clinical Infectious Diseases
    • 17 Jun 2020 Results published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top